A small trial of Eli Lilly’s donanemab showed the experimental Alzheimer’s drug slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.
A study published in the Journal of the American Medical Association shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.
Biogen filed a lawsuit against a New York life sciences company over alleged patent infringements related to the experimental Alzheimer’s disease treatment aducanumab.
A specially designed clinical study that was the first disease prevention trial to study Alzheimer’s disease drugs with different mechanisms of action from two different pharmaceutical companies failed to hit the primary endpoint.
Investigators at the Case Western Reserve University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.
Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.
Shares of Eisai Co. Ltd. plunged as much as 21 percent after the results of the company’s experimental Alzheimer’s drug being developed with partner Biogen Inc. failed to enthuse investors.
During a fireside chat at BIO International in San Diego in summer 2017, Daniel Skovronsky – now president of Lilly Research Labs – confirmed Eli Lilly’s commitment to finding an effective therapy for Alzheimer’s disease. Lilly continues to push forward. EP Vantage highlighted and analyzed the company’s five Phase I programs for Alzheimer’s disease. Much like what Skovronsky said about learning from the Phase III solanezumab failure, EP Vantage pointed to some of the hopes the Lilly programs have for blocking the development of amyloid plaques.